235 related articles for article (PubMed ID: 36432116)
21. Early interleukin-6 enhances hepatic ketogenesis in APP
Shi L; Zhao D; Hou C; Peng Y; Liu J; Zhang S; Liu J; Long J
Neurobiol Aging; 2017 Aug; 56():115-126. PubMed ID: 28528772
[TBL] [Abstract][Full Text] [Related]
22. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
23. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
25. Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway.
Jin J; Guo Y; Liu Y; Wang Z; Yang X; Sun S
Oncol Rep; 2019 Sep; 42(3):1183-1193. PubMed ID: 31233204
[TBL] [Abstract][Full Text] [Related]
26. Loss of HMGCS2 Enhances Lipogenesis and Attenuates the Protective Effect of the Ketogenic Diet in Liver Cancer.
Wang YH; Suk FM; Liao YJ
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32635582
[TBL] [Abstract][Full Text] [Related]
27. Role of ketone signaling in the hepatic response to fasting.
Geisler CE; Ghimire S; Bogan RL; Renquist BJ
Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G623-G631. PubMed ID: 30767679
[TBL] [Abstract][Full Text] [Related]
28. Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma.
Suk FM; Wang YH; Chiu WC; Liu CF; Wu CY; Chen TL; Liao YJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445279
[TBL] [Abstract][Full Text] [Related]
29. Ketogenesis alleviates TNFα-induced apoptosis and inflammatory responses in intestinal cells.
Kim JT; Napier DL; Kim J; Li C; Lee EY; Weiss HL; Wang Q; Evers BM
Free Radic Biol Med; 2021 Aug; 172():90-100. PubMed ID: 34087430
[TBL] [Abstract][Full Text] [Related]
30. Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis.
Asif S; Kim RY; Fatica T; Sim J; Zhao X; Oh Y; Denoncourt A; Cheung AC; Downey M; Mulvihill EE; Kim KH
Mol Metab; 2022 Jul; 61():101494. PubMed ID: 35421611
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
32. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
33. Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma.
Yang X; Liu J; Liang Q; Sun G
Fundam Clin Pharmacol; 2021 Aug; 35(4):690-699. PubMed ID: 33015852
[TBL] [Abstract][Full Text] [Related]
34. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
35. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
Liu G; Kuang S; Cao R; Wang J; Peng Q; Sun C
FASEB J; 2019 Sep; 33(9):10089-10103. PubMed ID: 31199678
[TBL] [Abstract][Full Text] [Related]
37. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
38. Ketogenesis contributes to intestinal cell differentiation.
Wang Q; Zhou Y; Rychahou P; Fan TW; Lane AN; Weiss HL; Evers BM
Cell Death Differ; 2017 Mar; 24(3):458-468. PubMed ID: 27935584
[TBL] [Abstract][Full Text] [Related]
39. Liver-Derived Ketogenesis via Overexpressing HMGCS2 Promotes the Recovery of Spinal Cord Injury.
Sun X; Zhang B; Sun K; Li F; Hu D; Chen J; Kong F; Xie Y
Adv Biol (Weinh); 2024 Feb; 8(2):e2300481. PubMed ID: 37990936
[TBL] [Abstract][Full Text] [Related]
40. DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Chen X; Yang G; Guo X; Zhang J; Sun W; Liu D; Wang H; Liu S
Oxid Med Cell Longev; 2022; 2022():2543220. PubMed ID: 35770048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
